Inicio › Cáncer de pulmón de células no pequeñas › Nueva York

Ensayos clínicos de Cáncer de pulmón de células no pequeñas en Nueva York

169 estudios sobre Cáncer de pulmón de células no pequeñas buscan participantes en Nueva York.

Ciudades en Nueva York

Texto oficial del estudio (inglés)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Northwell Health Imbert Cancer Center, Bay Shore
Maimonides Medical Center, Brooklyn
Roswell Park Cancer Institute, Buffalo
y 18 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Roswell Park Cancer Institute ( Site 0184), Buffalo
Hematology-Oncology Associates of CNY ( Site 0164), East Syracuse
The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216), New York
y 5 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06623422

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

New York Cancer & Blood Specialists - New Hyde Park, New Hyde Park
New York Cancer & Blood Specialists - Cancer Center - Research Headquarters, New York
New York Cancer & Blood Specialists - Patchogue Medical Oncology, Patchogue

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06472245

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Memorial Sloan Kettering Commack, Commack
Memorial Sloan Kettering Westchester, Harrison
New York Proton Center, New York
y 9 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07293247

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Columbia University Medical Center, New York
Memorial Sloan Kettering, New York

ReclutandoFase 1/2

Edades de 12 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT04585750

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
NYU Langone Medical Center - Perlmutter Cancer Center (NYU Cancer Institute), New York
Icahn School of Medicine at Mount Sinai, New York
y 2 más

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06465069

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Local Institution - 0080, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07680764

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

NYU Langone Hospital Long Island, Mineola
NYU Langone Hospital Manhattan, New York
Jacobi Medical Center - Albert Einstein College of Medicine, The Bronx
y 1 más

ReclutandoFase 2/3

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT07365319

A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors

START New York Long Island LLC, Lake Success

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 2 oct 2026 · NCT06270706

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Exelixis Clinical Site #60, New York
Exelixis Clinical Site #6, New York
Exelixis Clinical Site #76, Syracuse

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT05176483

A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

New York Oncology Hematology, P.C. ( Site 9000), Albany
White Plains Hospital ( Site 3213), White Plains

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07513376

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Roswell Park Cancer Institute IDS, Buffalo
Memorial Sloan Kettering Hospital, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06172478

Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial

Hematology Oncology Associates of CNY at Camillus, Camillus
Hematology Oncology Associates of Central New York-East Syracuse, East Syracuse
Stony Brook University Medical Center, Stony Brook

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07388524

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06625775

A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

New York Oncology Hematology P.C ( Site 9000), Albany

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07554339

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

New York Oncology Hematology, P.C. ( Site 0119), Albany
Wilmot Cancer Institute ( Site 0141), Rochester

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT07190248

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Montefiore Medical Center-Einstein Campus, The Bronx
Montefiore Medical Center-Weiler Hospital, The Bronx
Montefiore Medical Center - Moses Campus, The Bronx
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 1 oct 2026 · NCT06498635

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Memorial Sloan Kettering Cancer Center, New York
Optum Medical Care, PC, Westbury

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361497

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Local Institution - 0224, Laurelton
Memorial Sloan Kettering Cancer Center, New York
Optum Medical Care, PC, Westbury

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07361510

A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

NYU, New York
Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT07659782

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NYU Langone's Perlmutter Cancer Center, New York
Memorial Sloan Kettering Cancer Center, New York
Optum Medical Care, PC, Westbury

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 30 sept 2026 · NCT06765109

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Research Site, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT05877599

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

New York Cancer And Blood Specialists - Shirley /ID# 272547, Shirley

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06772623

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Roswell Park Cancer Institute, Buffalo
Memorial Sloan Kettering Cancer Center, New York
Montefiore Medical Center, The Bronx

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT06881784

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

Montefiore Medical Center - Montefiore Medical Park, The Bronx
White Plains Hospital, White Plains

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT07144280

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

Cayuga Medical Center ( Site 0086), Ithaca
University Hospital at Stony Brook ( Site 0054), Stony Brook
White Plains Hospital ( Site 0091), White Plains

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06312137

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

New York Oncology Hematology, Albany
New York Oncology Hematology, Clifton Park
Hematology Oncology Associates of Rockland, Nyack

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07222566

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Research Site, New York
Research Site, New York

ReclutandoFase 1

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06218914

A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer

New York University Langone Medical Center, New York

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07227025

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

NYU Langone Medical Center, New York

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04981119

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Hematology Oncology Associates of Rockland, Nyack

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06758401

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Hematology-Oncology Associates of CNY, East Syracuse
Laura & Isaac Perlmutter Cancer Center at NYU Langone Hospital - Long Island, Mineola
NYU Langone Health Laura and Isaac Perlmutter Cancer Center, New York
y 4 más

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06667076

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NYU Langone Health, New York
Memorial Sloan Kettering Cancer Center, New York

ReclutandoFase 2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06667908

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

Montefiore Medical Center- Montefiore Medical Park, The Bronx

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07227298

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Research Site, Buffalo
Research Site, East Syracuse
Research Site, Fresh Meadows
y 2 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Columbia University Irving Medical Center, New York
Memorial Sloan Kettering Cancer Center, New York
Northport VA Medical Center, Northport

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06890598

Pan-tumor MRD Study

Guthrie Lourdes Memorial Hospital (GLMH), Binghamton
New York Cancer & Blood Specialists, Shirley

ReclutandoEstudio observacional

Edades de 18 en adelante · Todos los sexos · Actualizado el 24 sept 2026 · NCT06605404

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Veterans Affairs New York Harbor Healthcare System, New York
University of Rochester Medical Center, Rochester
Local Institution - 0511, Schenectady
y 1 más

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

Research Site, Stony Brook

ReclutandoFase 3

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT06357533

Intratumoral N17350 in Advanced Solid Tumors

Roswell Park Comprehensive Cancer Center, Buffalo

ReclutandoFase 1/2

Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07339176

De ClinicalTrials.gov, datos obtenidos el 5 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.